Skip to main content
ACG 2024 Annual Meetings Posters Main banner
Back
Rate ePoster

Sunday Poster Session

Category: IBD

P0854 - The Hidden Burden of Fatigue in Moderate-to-Severe Crohn’s Disease and Ulcerative Colitis: Results From the Communicating Needs and Features of IBD Experiences (CONFIDE) Survey

Sunday, October 27, 2024
3:30 PM – 7:00 PM ET
Location: Exhibit Hall E
Has Audio
Stefan Schreiber, MD1, Alison Bleakman, 2, Theresa Gibble, PhD2, Marla C. Dubinsky, MD3, David Rubin, 4, Remo Panaccione, MD5, Toshifumi Hibi, MD, PhD6, Cem Kayhan, MD2, Tommaso Panni, PhD2, Angelo Favia, PhD2, Eoin Flynn, PhD2, Christian Atkinson, MRes7, Simon Travis, 8
1University Hospital, Kiel, Schleswig-Holstein, Germany; 2Eli Lilly and Company, Indianapolis, IN; 3Icahn School of Medicine at Mount Sinai, New York, NY; 4University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL; 5University of Calgary, Calgary, AB, Canada; 6Kitasato University, Tokyo, Japan, Shirokane, Minato-ku, Tokyo, Japan; 7Adelphi Real World, Bollington, England, United Kingdom; 8University of Oxford, Oxford, England, United Kingdom

Introduction: The Communicating Needs and Features of Inflammatory bowel disease (IBD) Experiences (CONFIDE) study explored experiences and impact of Crohn’s disease (CD)/Ulcerative colitis (UC)-related symptoms in Europe (EU5: France, Germany, Italy, Spain, and UK), the United States (US) and Japan. These analyses focus on EU5 and US patients (pts).

Methods: Online, quantitative, cross-sectional surveys were conducted among pts with moderate-to-severe CD/UC, defined by previous treatment, steroid use, and/or hospitalization. Fatigue over past 7 days was assessed using Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT–F) scale (range: 0–52). Manitoba IBD Index assessed pt-reported disease activity in last 6 months (6-level scale); disease was considered active if constantly-to-occasionally experienced symptoms (responses 1–4), and inactive if infrequent/absent (responses 5/6). Pt-reported impact of CD/UC on energy levels was reported on a scale of 1 (no impact)–7 (high impact).

Results: Total 547 EU5 (55.4% male, mean age: 38.0 years) and 215 US (54.9% male, 40.9 years) pts with CD and 556 EU5 (57.4% male, 38.9 years) and 200 US (61.5% male, 40.4 years) pts with UC completed the surveys. Overall, 34.2% EU5 and 35.8% US pts with CD, and 20.9% EU5 and 27.5% US pts with UC reported currently (in the last month) experiencing fatigue; overall >80% indicated that CD/UC negatively impacted their energy levels: CD, EU5: 80.1%, US: 84.2%; UC, EU5: 81.1%, US: 88.0%. Mean±SD FACIT-F scores: 27.4±11.3 and 26.8±10.8 for EU5 and US pts with CD, and 29.4±10.0 and 26.2±11.3 for EU5 and US pts with UC, respectively. FACIT-F scores among pts currently experiencing fatigue: 24.3±10.8 and 26.1±10.9 for EU5 and US pts with CD, and 26.0±10.6 and 24.5±11.5 for EU5 and US pts with UC. Of those currently experiencing fatigue, most pts with CD reported active disease (CD, EU5: 92.5%, US: 93.5%; UC, EU5: 92.2%, US: 98.1%). Among pts reporting ever experiencing fatigue (CD, EU5: 45.2%, US: 45.6%; UC, EU5: 30.6%, US: 40.0%), most reported experiencing fatigue at least once a week (CD, EU5: 67.5%, US: 79.6%; UC, EU5: 66.4%, US: 70.0%).

Discussion: EU5 and US pts with CD/UC reported severe fatigue (FACIT-F scores < 30), indicating major fatigue burden, which is clearly associated with pt-reported active disease. Both CD and UC negatively impact energy levels for most pts. The findings underscore the value of active fatigue management in CD/UC to improve pts’ quality of life.


Disclosures:
Stefan Schreiber: AbbVie – Consultant, Personal fees, Speakers Bureau. Amgen – Personal fees. Arena Pharmaceuticals – Consultant, Personal fees, Speakers Bureau. Biogen – Consultant, Personal fees, Speakers Bureau. Bristol Myers Squibb – Consultant, Personal fees, Speakers Bureau. Celgene – Consultant, Personal fees, Speakers Bureau. Celltrion – Consultant, Personal fees, Speakers Bureau. Eli Lilly and Company – Personal fees. Falk – Consultant, Personal fees, Speakers Bureau. Ferring Pharmaceuticals – Personal fees. Fresenius – Consultant, Personal fees, Speakers Bureau. Galapagos – Personal fees. Gilead – Consultant, Personal fees. Hikma Pharmaceuticals – Advisory Committee/Board Member, Consultant. I-MAB – Consultant, Personal fees. Janssen – Consultant, Personal fees, Speakers Bureau. Morphic – Personal fees. MSD – Consultant, Personal fees, Speakers Bureau. Mylan – Consultant, Personal fees. Novartis – Personal fees. Pfizer Inc – Consultant, Personal fees, Speakers Bureau. Protagonist – Consultant, Personal fees. Provention Bio – Consultant, Personal fees. Roche – Personal fees. Sandoz/Hexal – Personal fees. Shire – Personal fees. Takeda – Consultant, Personal fees, Speakers Bureau. Theravance Biopharma – Consultant, Personal fees. Ventyx – Consultant, Personal fees.
Alison Bleakman: Eli Lilly and Company – Employee, Stock Options.
Theresa Gibble: Eli Lilly and Company – Employee, Stock Options.
Marla Dubinsky: AbbVie – Consultant. Abivax – Consultant. Arena – Consultant. AstraZeneca – Consultant. Bristol Myers Squibb – Consultant. Celgene – Consultant. Eli Lilly – Consultant. Genentech – Consultant. Gilead – Consultant. Janssen – Consultant. Pfizer Inc – Consultant. Prometheus Labs – Consultant. Takeda – Consultant.
David Rubin: AbbVie – Consultant. Allergan – Consultant. Altrubio – Stock Options. Altrubio Inc. – Consultant. American College of Gastroenterology – Consultant. Arena Pharmaceuticals – Consultant. Athos Therapeutics – Consultant. Bellatrix Pharmaceuticals – Consultant. Boehringer Ingelheim International GmbH – Consultant. Bristol Myers Squibb – Consultant. Celgene Corp/Syneos – Consultant. Cornerstones Health – Consultant. Datos Health – Stock Options. Eli Lilly and Company – Consultant. GalenPharma/Atlantica – Consultant. Genentech/Roche – Consultant. Gilead Sciences – Consultant. GODURN – Consultant. Inc. (non-profit) – Consultant. InDex Pharmaceuticals – Consultant. Ironwood Pharmaceuticals – Consultant. Iterative Scopes – Consultant. Janssen – Consultant. LLC – Consultant. Materia Prima – Consultant. Pfizer – Consultant. Prometheus Biosciences – Consultant. Reistone Biopharma – Consultant. Takeda – Consultant, Grant/Research Support. Techlab Inc – Consultant.
Remo Panaccione: Élan – Consultant. Abbivax – Consultant. Abbott – Consultant. AbbVie – Advisory Committee/Board Member, Consultant, Speaking Fees. Alimentiv – Advisory Committee/Board Member, Consultant. Amgen – Advisory Committee/Board Member, Consultant, Speaker Fees. Arena Pharmaceuticals – Advisory Committee/Board Member, Consultant, Speaker Fees. AstraZeneca – Advisory Committee/Board Member, Consultant. Biogen – Advisory Committee/Board Member, Consultant. Boehringer Ingelheim – Advisory Committee/Board Member, Consultant. Bristol Myers Squibb – Advisory Committee/Board Member, Consultant, Speaker Fees. Celgene – Advisory Committee/Board Member, Consultant, Speaker Fees. Celltrion – Consultant. Cosmos Pharmaceuticals – Consultant. Eisai – Consultant. Ferring – Advisory Committee/Board Member, Consultant, Speaker Fees. Fresenius Kabi – Advisory Committee/Board Member, Consultant, Speaker Fees. Galapagos – Consultant. Genentech – Advisory Committee/Board Member, Consultant. Gilead – Advisory Committee/Board Member, Consultant, Speaker Fees. GlaxoSmithKline – Advisory Committee/Board Member, Consultant. JAMP Bio – Advisory Committee/Board Member, Consultant. Janssen – Advisory Committee/Board Member, Consultant, Speaker Fees. Lilly – Advisory Committee/Board Member, Consultant, Speaker Fees. Merck – Advisory Committee/Board Member, Consultant, Speaker Fees. Mylan – Advisory Committee/Board Member, Consultant. Novartis – Advisory Committee/Board Member, Consultant. Oppilan Pharma – Advisory Committee/Board Member, Consultant. Organon – Advisory Committee/Board Member, Consultant, Speaker Fees. Pandion Pharma – Advisory Committee/Board Member, Consultant. Pendopharm – Consultant. Pfizer Inc – Advisory Committee/Board Member, Consultant, Speaker Fees. Progenity – Advisory Committee/Board Member, Consultant. Prometheus Biosciences – Consultant. Protagonist Therapeutics – Advisory Committee/Board Member, Consultant. Roche – Advisory Committee/Board Member, Consultant, Speaker Fees. Sandoz – Advisory Committee/Board Member, Consultant, Speaker Fees. Satisfai Health – Consultant. Shire – Advisory Committee/Board Member, Consultant, Speaker Fees. Sublimity Therapeutics – Advisory Committee/Board Member, Consultant. Takeda – Advisory Committee/Board Member, Consultant, Speaker Fees. Theravance – Consultant. Trellus – Consultant. UCB – Consultant. Ventyx – Advisory Committee/Board Member, Consultant. Viatris – Consultant.
Toshifumi Hibi: AbbVie GK – Grant/Research Support. ActivAid – Grant/Research Support. Alfresa Pharma Corporation – Grant/Research Support, study group sponsorship. Bristol-Myers Squibb – Grant/Research Support. Celltrion – Advisory/consultancy fees. EA Pharma – Lecture fees. Eli Lilly and Company – Grant/Research Support, Advisory/consultancy fees. Ferring Pharmaceuticals – Grant/Research Support. Gilead Sciences – Grant/Research Support. Janssen – Grant/Research Support. JIMRO – study group sponsorship and lecture fees. JMDC Inc. – Grant/Research Support. Kyorin – study group sponsorship and lecture fees. Mitsubishi-Tanabe Pharma Corporation – Advisory/consultancy fees and lecture fees. MIYARISAN Pharmaceutical – study group sponsorship. Mochida Pharmaceutical – Grant/Research Support, study group sponsorship and lecture fees. Nippon Kayaku Co. – Grant/Research Support. Pfizer – Grant/Research Support, Lecture fees. Takeda Pharmaceutical – Grant/Research Support, Advisory/consultancy fees and lecture fees. Zeria Pharmaceutical – study group sponsorship and lecture fees.
Cem Kayhan: Eli Lilly and Company – Employee, Stock Options.
Tommaso Panni: Eli Lilly and Company – Employee. Eli Lilly and Company – Employee, Stock Options. Eli Lilly and Company – Stock Options.
Angelo Favia: Eli Lilly and Company – Employee, Stock Options.
Eoin Flynn: Eli Lilly and Company – Employee, Stock Options.
Christian Atkinson: Adelphi Real World – Employee. Eli Lilly and Company (in connection with this study) – Consultant.
Simon Travis: AbbVie – Grant/Research Support. Buhlmann – Grant/Research Support. ECCO – Grant/Research Support. Eli Lilly and Company – Grant/Research Support. Ferring Pharmaceuticals – Grant/Research Support. International Organization for the Study of IBD – Grant/Research Support. Janssen – Grant/Research Support. MSD – Grant/Research Support. Normal Collision Foundation – Grant/Research Support. Pfizer – Grant/Research Support. Procter & Gamble – Grant/Research Support. Schering-Plough – Grant/Research Support. Takeda – Grant/Research Support. UCB – Grant/Research Support. Vifor Pharma – Grant/Research Support. Warner Chilcott – Grant/Research Support.


Stefan Schreiber, MD1, Alison Bleakman, 2, Theresa Gibble, PhD2, Marla C. Dubinsky, MD3, David Rubin, 4, Remo Panaccione, MD5, Toshifumi Hibi, MD, PhD6, Cem Kayhan, MD2, Tommaso Panni, PhD2, Angelo Favia, PhD2, Eoin Flynn, PhD2, Christian Atkinson, MRes7, Simon Travis, 8. P0854 - The Hidden Burden of Fatigue in Moderate-to-Severe Crohn’s Disease and Ulcerative Colitis: Results From the Communicating Needs and Features of IBD Experiences (CONFIDE) Survey, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.